And the company might one day follow Galapagos into decentralised manufacturing.

The group claims a seven-day vein-to-vein time is unique, and says why this matters.

Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.

A CD22-directed Car that has had several owners will next year deliver its most important dataset.

First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.

AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.

Kura will see more combo data, while a new contender from Sumitomo emerges.

Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.

Reports of Arc-10's failure are greatly exaggerated, the company argues.